Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with daratumumab-len-dex

被引：0
|
作者：
Giannotta, Claudia [1 ]
Ziccheddu, Bachisio [2 ]
D'Agostino, Mattia [3 ,4 ]
Bertuglia, Giuseppe [5 ]
Saraci, Elona [5 ]
Oliva, Stefania [5 ]
Bolli, Niccolo' [6 ]
Landgren, Ola [7 ]
Bruno, Benedetto [3 ,4 ]
Boccadoro, Mario [8 ]
Maura, Francesco [7 ]
Massaia, Massimo [1 ]
Larocca, Alessandra [5 ]
机构：
[1] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr Guido Tarone, Lab Blood Tumor Immunol, Turin, Italy
[2] Univ Miami, Coral Gables, FL 33124 USA
[3] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[4] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[5] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Ematol U, Myeloma Unit, Turin, Italy
[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Milan, Italy
[7] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Cattedra Ematol, Hematol Div, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-392
引用
收藏
页码：S256 / S257
页数：2
相关论文
共 50 条
  • [41] Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Luider, Joanne
    Tay, Jason
    Bahlis, Nizar J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E67 - E68
  • [42] Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Usmani, Saad
    Weiss, Brendan
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk
    Voorhees, Peter M.
    Richardson, Paul G.
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2015, 126 (23)
  • [43] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [44] Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
    Lakshman, Arjun
    Abeykoon, Jithma P.
    Kumar, Shaji K.
    Rajkumar, S. Vincent
    Dingli, David
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Leung, Nelson
    Dispenzieri, Angela
    Kourelis, Taxiarchis V.
    Go, Ronald S.
    Lacy, Martha Q.
    Hobbs, Miriam A.
    Lin, Yi
    Warsame, Rahma
    Lust, John
    Fonder, Amie L.
    Hwa, Yi L.
    Hayman, Suzanne R.
    Russell, Stephen J.
    Kyle, Robert A.
    Gertz, Morie A.
    Kapoor, Prashant
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (11) : 1146 - 1155
  • [45] Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Weiss, Brendan M.
    Plesner, Torben
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk M.
    Voorhees, Peter M.
    Richardson, Paul G.
    Chari, Ajai
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa M.
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2016, 128 (01) : 37 - 44
  • [46] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience
    Fucci, Ludovica
    Gensini, Lorenzo
    Coppetelli, Ugo
    La Barbera, Elettra Ortu
    Gentile, Martina
    Fiori, Luciano
    Perrone, Salvatore
    Cimino, Giuseppe
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [47] DARATUMUMAB IN MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL CLINICAL PRACTICE IN CATALONIA
    Moreno, David Fernando
    Gomez-Hernando, Marta
    Clapes, Victoria
    Soler, Juan Alfons
    Gonzalez-Montes, Yolanda
    Gironella, Mercedes
    Motllo, Cristina
    Granell, Miquel
    Abella, Eugenia
    Garcia-Pintos, Marta
    Garcia-Guinon, Antoni
    Cabezudo, Elena
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 138 - 139
  • [48] DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Lakshman, A.
    Abeykoon, J.
    Kumar, S.
    Rajkumar, V.
    Kourelis, T.
    Buadi, F.
    Dingli, D.
    Martha, L.
    Gonsalves, W.
    Dispenzieri, A.
    Kyle, R.
    Lin, Y.
    Go, R.
    Warsame, R.
    Hobbs, M.
    Fonder, A.
    Hwa, Y.
    Hayman, S.
    Russell, S.
    Leung, N.
    Gertz, M.
    Kapoor, P.
    HAEMATOLOGICA, 2017, 102 : 508 - 508
  • [49] Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
    Frerichs, Kristine A.
    Verkleij, Christie P. M.
    Dimopoulos, Meletios A.
    Marin Soto, Jhon A.
    Zweegman, Sonja
    Young, Mary H.
    Newhall, Kathryn J.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    CANCERS, 2021, 13 (10)
  • [50] Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy
    Burbury, Kate
    Gambell, Peter C.
    Choo, Amanda
    Cumow, Jennifer
    Lynch, Kevin
    Harrison, Simon J.
    Quach, Hang
    Ritchie, David
    Prince, Miles
    Westerman, David Alan A.
    BLOOD, 2010, 116 (21) : 1309 - 1310
12345